Last updated on March 2019

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cerebrovascular accident | Cerebral Edema
  • Age: Between 18 - 85 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. A clinical diagnosis of acute ischemic stroke in the middle cerebral artery (MCA) territory
  2. A large hemispheric infarction defined as; lesion volume of 80 to 300 centimeters cubed (cm^3) on magnetic resonance imaging (MRI) diffusion-weighted imaging (DWI), or computed tomography perfusion (CTP), or an Alberta Stroke Program Early CT Score (ASPECTS) of 1 to 5 with involvement of at least 2 defined cortical regions
  3. Screening National Institutes of Health Stroke Scale (NIHSS) >=10
  4. Study treatment infusion within 10 hours after time of symptom onset, if known, or the time last known normal
  5. For participants who receive thrombectomy, inclusion into the study must be based on post-thrombectomy MRI-DWI

Exclusion Criteria:

  1. Participant is likely to have supportive care withdrawn on the first day
  2. Commitment to decompressive craniectomy (DC) prior to enrollment
  3. Evidence of concurrent infarction in the contralateral hemisphere sufficiently serious so as to affect functional outcome

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.